.
Since the discovery of penicillin in 1929 (Ref. 2), other, more effective antimicrobials have been discovered and developed by elucidation of drug-target interactions and by drug molecule modification. These efforts have greatly enhanced our clinical armamentarium. Antibioticmediated cell death, however, is a complex process that begins with the physical interaction between a drug molecule and its specific target in bacteria, and involves alterations to the affected bacterium at the biochemical, molecular and ultrastructural levels. The increasing prevalence of drug-resistant bacteria 3 , as well as the increased means of gaining resistance, has made it crucial to better understand the multilayered mechanisms by which currently available antibiotics kill bacteria, as well as to explore and find alternative antibacterial therapies.
Antibiotic-induced cell death has been associated with the formation of double-stranded DNA breaks following treatment with inhibitors of topoisomerase II (also known as DNA gyrase) 4 , with the arrest of DNA-dependent RNA synthesis following treatment with rifamycins 5 , with cell envelope damage and loss of structural integrity following treatment with inhibitors of cell wall synthesis 6 , and with cellular energetics, ribosome binding and protein mistranslation following treatment with inhibitors of protein synthesis 7 . In addition, recent evidence points towards a common mechanism of cell death involving disadvantageous cell responses to druginduced stresses that are shared by all classes of bactericidal antibiotics, which ultimately contributes to killing by these drugs 8 . Specifically, treatment with lethal concentrations of bactericidal antibiotics results in the production of harmful hydroxyl radicals through a common oxidative damage cell death pathway that involves alterations in central metabolism (that is, in the tricarboxylic acid (TCA) cycle) and iron metabolism [8] [9] [10] . In this Review we describe our current knowledge of the drug-target interactions and the associated mechanisms by which the main classes of bactericidal antibiotics kill bacteria. We also describe recent efforts in network biology that have yielded new mechanistic insights into how bacteria respond to lethal antibiotic treatments, and discuss how these insights and related developments in synthetic biology could be used to develop new, effective means to combat bacterial infections.
Inhibition of DNA replication by quinolones DNA synthesis, mRNA transcription and cell division require the modulation of chromosomal supercoiling through topoisomerase-catalysed strand breakage and rejoining reactions 14, 15 . Quinolones are derivatives of nalidixic acid, which was discovered as a byproduct of the synthesis of chloroquine (a quinine) and was introduced in the 1960s to treat urinary tract infections 16 . Nalidixic acid and other first generation quinolones (for example, oxolinic acid) are rarely used today owing to their toxicity 17 . Second (ciprofloxacin), third (levofloxacin) and fourth (gemifloxacin) generation quinolone antibiotics (TABLe 1) can be classified on the basis of their chemical structure and of qualitative differences between the killing mechanisms they use 16, 18 . The quinolone class of antimicrobials interferes with the maintenance of chromosomal topology by targeting topoisomerase II and topoisomerase Iv, trapping these enzymes at the DNA cleavage stage and preventing strand rejoining 4, 19, 20 (fIG. 1) . Despite the general functional similarities between topoisomerase II and topoisomerase Iv, their susceptibility to quinolones varies across bacterial species 20 (TABLe 1) . For example, several studies have shown that topo isomerase Iv is the primary target of quinolones in Gram-positive bacteria (for example, Streptococcus pneumoniae 21 ), whereas in Gram-negative bacteria (for example, Escherichia coli 13 and Neisseria gonorrhoea 22 ) their primary target is topoisomerase II (and topoisomerase Iv is the secondary target).
Introduction of DNA breaks and replication fork arrest.
The ability of quinolone antibiotics to kill bacteria is a function of the stable interaction complex that is formed between drug-bound topoisomerases and cleaved DNA 4 . On the basis of studies using DNA cleavage mutants of topoisomerase II 23 and topoisomerase Iv 24 that do not prevent quinolone binding, and studies that have shown that strand breakage can occur in the presence of quinolones 25 , it is accepted that DNA strand breakage occurs after the drug has bound to the enzyme. Therefore, the net effect of quinolone treatment is to generate double-stranded DNA breaks that are trapped by covalently (but reversibly) linked topoisomerases, the function of which is compromised [26] [27] [28] . As a result of quinolone-topoisomerase-DNA complex formation, the DNA replication machinery becomes arrested at blocked replication forks, leading to inhibition of DNA synthesis, which immediately leads to bacteriostasis and eventually cell death 4 (fIG. 1). It should be noted that the effects on DNA replication that correlate with bacteriostatic concentrations of quinolones are thought to be reversible 4, 29 . Nonetheless, considering that topoisomerase II has been found to be distributed approximately every 100 kb along the chromosome 30 , inhibition of topoisomerase function by quinolone antibiotics and the resulting formation of stable complexes with DNA have substantial negative consequences for the cell in terms of its ability to deal with drug-induced DNA damage 31 .
The role of protein expression in quinolone-mediated cell death. The introduction of double-stranded DNA breaks following topoisomerase inhibition by quinolones induces the DNA stress response (SOS response), in which RecA is activated by DNA damage and promotes self-cleavage of the lexA repressor protein, inducing the expression of SOS response genes such as DNA repair enzymes 32 . Notably, several studies have shown that preventing the induction of the SOS response enhances killing by quinolones (except in the case of nalidixic acid) 8, 33 . Preventing the activation of the SOS response has also been shown to reduce the formation of drug-resistant mutants by blocking the induction of error-prone DNA polymerases 34 , homologous recombination 20 and horizontal transfer of drug-resistance elements 35, 36 . Together with studies revealing that co-treatment with quinolones and the protein synthesis inhibitor chloramphenicol inhibits the ability of quinolones to kill bacteria 19, 37 , there seems to be a clear relationship between the
SOS response
The DNA stress response pathway in E. coli, the prototypical network of genes of which is regulated by the transcriptional repressor LexA, and is commonly activated by the co-regulatory protein RecA, which promotes LexA self-cleavage when activated. primary effects of quinolone-topoisomerase-DNA complex formation and the response of the bacteria (through the stress-induced expression of proteins) to these effects in the bactericidal activity of quinolone antibiotics. For example, the contribution of reactive oxygen species (ROS) to quinolone-mediated cell death has recently been shown to occur in a protein synthesis-dependent manner 38 . Also, the chromosome-encoded toxin MazF has been shown to be required under certain conditions for efficient killing by quinolones owing to its ability to alter protein carbonylation 39 , a form of oxidative stress 40 .
Inhibition of RNA synthesis by rifamycins
The inhibition of RNA synthesis by the rifamycin class of semi-synthetic bactericidal antibiotics, similarly to the inhibition of DNA replication by quinolones, has a catastrophic effect on prokaryotic nucleic acid metabolism and is a potent means of inducing bacterial cell death 5 . Rifamycins inhibit DNA-dependent transcription by stably binding with high affinity to the β-subunit (encoded by rpoB) of a DNA-bound and actively transcribing RNA polymerase [41] [42] [43] (TABLe 1) . The β-subunit is located in the channel that is formed by the RNA polymerase-DNA complex, from which the newly synthesized RNA strand emerges 44 . Rifamycins uniquely require RNA synthesis to not have progressed beyond the addition of two ribonucleotides; this is attributed to the ability of the drug molecule to sterically inhibit nascent RNA strand initialization 45 . It is worth noting that rifamycins are not thought to act by blocking the elongation step of This leads to the formation of double-stranded DNA breaks and cell death in either a protein synthesis-dependent or protein synthesis-independent manner. β-lactams inhibit transpeptidation by binding to penicillin-binding proteins (PBPs) on maturing peptidoglycan strands. The decrease in peptidoglycan synthesis and increase in autolysins leads to lysis and cell death. Aminoglycosides bind to the 30S subunit of the ribosome and cause misincorporation of amino acids into elongating peptides. These mistranslated proteins can misfold, and incorporation of misfolded membrane proteins into the cell envelope leads to increased drug uptake. This, together with an increase in ribosome binding, has been associated with cell death.
Lysis
Rupture of the cell envelope leading to the expulsion of intracellular contents into the surrounding environment with eventual disintegration of the cell envelope.
Peptidoglycan hydrolase
An enzyme that introduces cuts between carbon-nitrogen non-peptide bonds while pruning the peptidoglycan layer. It is important for homeostatic peptidoglycan turnover.
Autolysin
An enzyme that hydrolyses the β-linkage between the monosaccharide monomers in peptidoglycan units and can induce lysis when in excess.
RNA synthesis, although a recently discovered class of RNA polymerase inhibitors (based on the compound CBR703) could inhibit elongation by allosterically modifying the enzyme 46 . Rifamycins were first isolated 47 from the Gram-positive bacterium Amycolatopsis mediterranei (originally known as Streptomyces mediterranei) in the 1950s. Mutagenesis of this organism has led to the isolation and characterization of more potent rifamycin forms 48 , including the clinically relevant rifamycin Sv and rifampicin. Rifamycins are considered bactericidal against Gram-positive bacteria and bacteriostatic against Gram-negative bacteria, a difference that has been attributed to drug uptake and not to affinity of the drug with the RNA polymerase β-subunit 49 . Notably, rifamycins are among the first-line therapies used against myco bacteria because they efficiently induce mycobacterial cell death 50 , although rifamycins are often used in combinatorial therapies owing to the rapid nature of resistance development 49, 51 . Interestingly, an interaction between DNA and the hydroquinone moiety of RNA polymerase-bound rifamycin has been observed 52 , and this interaction has been attributed to the location of the rifamycin molecule in relation to DNA in the DNA-RNA polymerase complex 42 . This proximity, coupled with the reported ability of rifamycin to cycle between a radical and nonradical form (rifamycin Sv and rifamycin S 52, 53 ), may damage DNA through a direct drug-DNA interaction. This hypothesis could account for the observation that rifamycin Sv can induce the SOS DNA damage response in E. coli and that treatment of recA-mutant E. coli results in cell death whereas treatment of wild-type E. coli leads to bacteriostasis 8 .
Inhibition of cell wall synthesis
Lytic cell death. The bacterial cell is encased by layers of peptidoglycan (also known as murein), a covalently crosslinked polymer matrix that is composed of peptide-linked β-(1-4)-N -acetyl hexosamine 54 . The mechanical strength afforded by this layer of the cell wall is crucial to a bacterium's ability to survive environmental conditions that can alter prevailing osmotic pressures; of note, the degree of peptidoglycan cross-linking correlates with the structural integrity of the cell 55 . Maintenance of the peptidoglycan layer is accomplished by the activity of transglycosylases and penicillin-binding proteins (PBPs; also known as transpeptidases), which add disaccharide pentapeptides to extend the glycan strands of existing peptidoglycan molecules and cross-link adjacent peptide strands of immature peptidoglycan units, respectively 56 . β-lactams and glycopeptides are among the classes of antibiotics that interfere with specific steps in homeostatic cell wall biosynthesis. Successful treatment with a cell wall synthesis inhibitor can result in changes to cell shape and size, induction of cell stress responses and ultimately cell . 1) . For example, β-lactams (including penicillins, carbapenems and cephalosporins) block the crosslinking of peptidoglycan units by inhibiting the peptide bond formation reaction that is catalysed by PBPs 55, 57, 58 . This inhibition is achieved by penicilloylation of the PBP active site -the β-lactam (containing a cyclic amide ring) is an analogue of the terminal d-alanyl-d-alanine dipeptide of peptidoglycan and acts as a substrate for the PBP during the acylation phase of cross link formation. Penicilloylation of the PBP active site blocks the hydrolysis of the bond created with the now ring-opened drug, thereby disabling the enzyme 59, 60 . By contrast, most actinobacterium-derived glycopeptide antibiotics (for example, vancomycin) inhibit peptidoglycan synthesis by binding peptidoglycan units (at the d-alanyl-d-alanine dipeptide) and by blocking transglycosylase and PBP activity 61 . In this way, glycopeptides (whether free in the periplasm like vancomycin or membrane-anchored like teicoplanin 62 ) generally act as steric inhibitors of peptidoglycan maturation and reduce the mechanical strength of the cell, although some chemically modified glycopeptides have been shown to directly interact with the transglycosylase 63 . It is worth noting that β-lactams can be used to treat Gram-positive and Gram-negative bacteria, whereas glycopeptides are effective against only Gram-positive bacteria owing to low permeability (TABLe 1) . In addition, antibiotics that inhibit the synthesis (for example, fosfomycin) and transport (for example, bacitracin) of individual peptidoglycan units are also currently in use, as are lipopeptides (for example, daptomycin), which affect structural integrity by inserting themselves into the cell membrane and inducing membrane depolarization.
Research into the mechanism of killing by peptidoglycan synthesis inhibitors has centred on the lysis event. Initially, it was thought that inhibition of cell wall synthesis by β-lactams caused cell death when internal pressure built up owing to cell growth outpacing cell wall expansion, resulting in lysis 6 . This unbalanced growth hypo thesis was based in part on the notion that active protein synthesis is required for lysis to occur following the addition of β-lactams.
The lysis-dependent cell death mechanism, however, has proven to be much more complex, involving many active cellular processes. Seminal work showed that S. pneumoniae deficient in amidase activity (possessed by peptidoglycan hydrolase or autolysins) did not grow or die following treatment with a lysis-inducing concentration of a β-lactam, an effect known as antibiotic tolerance 64 . Autolysins are membrane-associated enzymes that break down bonds between and within peptidoglycan strands, making them important during normal cell wall turnover and maintenance of cell shape 55 . Autolysins have also been shown to play a part in lytic cell death in bacterial species that contain numerous peptidoglycan hydrolases, such as E. coli 65 . In E. coli, a set of putative peptidoglycan hydrolases (lytM domain factors) were shown to be important for rapid ampicillin-mediated lysis 66 . The discovery that autolysins contribute to cell death expanded our understanding of lysis and showed that active degradation of the peptidoglycan layer by peptidoglycan hydrolases, in conjunction with inhibition of peptidoglycan synthesis by a β-lactam antibiotic, triggers lysis 64 (fIG. 1) .
Non-lytic cell death. S. pneumoniae lacking peptidoglycan hydrolase activity can still be killed by β-lactams, but at a slower rate than autolysin-active cells, indicating that
Two-component system
A two-protein signal relay system composed of a sensor histidine kinase and a cognate receiver protein, which is typically a transcription factor.
there is a lysis-independent mode of killing induced by β-lactams 64, 67 . evidence suggests that some of these nonlytic pathways are regulated by bacterial two-component systems 68 . For example, in S. pneumoniae, the vncSR twocomponent system controls the expression of the autolysin lytA and regulates tolerance to vancomycin and penicillin through lysis-dependent 69 and lysis-independent 70 cell death pathways.
In Staphylococcus aureus, the lytSR two-component system can similarly affect cell lysis by regulating autolysin activity 71 . lytR activates the expression of lrgAB 72 , which was found to inhibit autolysin activity and thereby lead to antibiotic tolerance 73 . lrgA is similar to bacteriophage holin proteins 73 , which regulate the access of autolysins to the peptidoglycan layer. Based on this information, an additional holin-like system, cidAB, was uncovered in S. aureus and found to activate autolysins, rendering S. aureus more susceptible to β-lactam-mediated killing 74, 75 . Complementation of cidA into a cidA-null strain reversed the loss of autolysin activity but did not completely restore sensitivity to β-lactams 74 .
Role of the SOS response in cell death by β-lactams.
Treatment with β-lactams leads to changes in cell morphology that are associated with the primary drug-PBP interaction. Generally speaking, PBP1 inhibitors cause cell elongation and are potent triggers of lysis, PBP2 inhibitors alter cell shape but do not cause lysis and PBP3 inhibitors influence cell division and can induce filamentation 76 . Interestingly, β-lactam subtypes have distinct affinities for certain PBPs, which correlate with the ability of these drugs to stimulate autolysin activity and induce lysis 76, 77 . Accordingly, PBP1-binding β-lactams are also the most effective inducers of peptidoglycan hydrolase activity, and PBP2 inhibitors are the least proficient autolysin activators 77 . Filamentation can occur following the activation of the DNA damage-responsive SOS network of genes 78 owing to expression of SulA, a key component of the SOS network that inhibits septation and leads to cell elongation by binding to and inhibiting polymerization of septationtriggering FtsZ monomers 79, 80 . Interestingly, β-lactams that inhibit PBP3 and induce filamentation have been shown to stimulate the DpiAB two-component system, which can activate the SOS response 81 . β-lactam lethality can be enhanced by disrupting DpiAB signalling or by knocking out sulA. This indicates that SulA may protect against β-lactam killing by shielding FtsZ and limiting a division ring interaction among PBPs and peptidoglycan hydrolases. In support of this idea, SulA expression limits the lysis observed in a strain of E. coli that expresses FtsZ84 (a mutant of FtsZ that is active only under certain temperatures and media conditions) and lacks PBP4 and PBP7 (Ref. 82) .
DNA-damaging antimicrobials that do not directly disrupt peptidoglycan turnover, such as quinolones, also cause filamentation by activating the SOS response 4 . Interestingly, a mutant strain of E. coli that is deficient in diaminopimelic acid synthesis (E. coli W7), a key building block of peptidoglycan, undergoes lysis following treatment with the fluoroquinolone antimicrobials ofloxacin or pefloxacin 83 . This suggests that peptidoglycan turnover and the SOS response could have a role in antibiotic-mediated lytic killing responses.
Inhibition of protein synthesis
The process of mRNA translation occurs over three sequential phases (initiation, elongation and termination) that involve the ribosome and a range of cytoplasmic accessory factors 84 . The ribosome is composed of two ribonucleoprotein subunits, the 50S and 30S, which assemble (during the initiation phase) following the formation of a complex between an mRNA transcript, N-formylmethionine-charged aminoacyl tRNA, several initiation factors and a free 30S subunit 85 . Drugs that inhibit protein synthesis are among the broadest classes of antibiotics and can be divided into two subclasses: the 50S inhibitors and 30S inhibitors (TABLe 1) .
50S ribosome inhibitors include macrolides (for example, erythromycin), lincosamides (for example, clindamycin), streptogramins (for example, dalfopristinquinupristin), amphenicols (for example, chloramphenicol) and oxazolidinones (for example, linezolid) 86, 87 . 50S ribosome inhibitors work by physically blocking either initiation of protein translation (as is the case for oxazolidinones 88 ) or translocation of peptidyl tRNAs, which serves to inhibit the peptidyltransferase reaction that elongates the nascent peptide chain. A model for the mechanism by which these drugs act has been formulated by studies of macrolides, lincosamides and streptogramins. The model involves blocking the access of peptidyl tRNAs to the ribosome (to varying degrees), subsequent blockage of the peptidyltransferase elongation reaction by steric inhibition and eventually triggering dissociation of the peptidyl tRNA 89, 90 . This model also accounts for the phenomenon that these classes of drugs lose their antibacterial activity when elongation has progressed beyond a crucial length 91 . 30S ribosome inhibitors include tetracyclines and amino cyclitols. Tetracyclines work by blocking the access of aminoacyl tRNAs to the ribosome 92 . The aminocyclitol class comprises spectinomycin and aminoglycosides (for example, streptomycin, kanamycin and gentamicin), which bind the 16S rRNA component of the 30S ribosome subunit. Spectinomycin interferes with the stability of peptidyl tRNA binding to the ribosome by inhibiting elongation factor-catalysed translocation, but does not cause protein mistranslation [93] [94] [95] . By contrast, the interaction between aminoglycosides and the 16S rRNA can induce an alteration in the conformation of the complex formed between an mRNA codon and its cognate charged aminoacyl tRNA at the ribosome. This promotes tRNA mismatching, which can result in protein mistranslation [96] [97] [98] [99] . Among ribosome inhibitors, naturally derived aminoglycosides are the only class that is broadly bactericidal. Macrolides, streptogramins, spectinomycin, tetracyclines, chloramphenicol and macrolides are typically bacteriostatic; however, they can be bactericidal in a species-or treatment-specific manner. For example, chloramphenicol has been shown to kill S. pneumoniae and Neisseria meningitidis effectively 100 , and chloramphenicol
Quinone pool
Membrane-associated cyclic aromatic-based compounds that shuttle electrons along the electron transport chain. and the macrolide azythromycin have exhibited bactericidal activity against Haemophilus influenzae 100, 101 . This species-specific variability in ribosome inhibitor-mediated cell death probably has to do with sequence differences among bacterial species in the variable regions of the highly conserved ribosomal proteins and RNAs 102 . In addition, high concentrations of macrolides and combinations of streptogramin group A and group B can behave in a bactericidal manner. For the rest of this section, however, we focus on aminoglycosides, which have the best-studied mechanism of killing by ribosome inhibition.
Aminoglycoside uptake and cell death. Binding of aminoglycosides to the ribosome does not bring translation to an immediate standstill. Instead, as noted above, this class of drugs promotes protein mistranslation through the incorporation of inappropriate amino acids into elongating peptide strands 96 ; this phenotype is specific for aminoglycosides and contributes to cell killing (fIG. 1) .
Respiration also has a crucial role in aminoglycoside uptake and lethality 103 . Following the initial step of drug molecule adsorption (in Gram-negative species such as E. coli) through electrostatic interaction, changes in membrane potential allow aminoglycosides to access the cell. Respiration-dependent uptake relies on the activity of membrane-associated cytochromes and maintenance of the electrochemical potential through the quinone pool 104, 105 . Accordingly, under anaerobic conditions aminoglycoside uptake is severely limited in both Gram-positive and Gram-negative bacteria 106, 107 , although there is evidence that aminoglycoside uptake can occur under certain anaerobic conditions by a mechanism that is sensitive to nitrate levels. In E. coli and Pseudomonas aeruginosa, aminoglycoside uptake can take place when nitrate is used as an electron acceptor in place of oxygen, and anaerobic bacteria that have quinones and cytochromes can take up aminoglycosides if sufficient anaerobic electron transport occurs 108 .
In E. coli aminoglycoside-mediated killing has been linked with alterations to the cell membrane ultrastructure that ultimately increase drug uptake 109, 110 . Aminoglycosides can affect membrane composition through the incorporation of mistranslated membrane proteins into the cytoplasmic membrane, thereby increasing cell permeability, which allows increased access of the drug 103 ( fIG. 1) . Sufficient aminoglycoside uptake resulting in increased ribosome inhibition and cell death could also occur as a function of the changes in membrane integrity owing to the incorporation of mistranslated membrane proteins 103 . An alteration in membrane permeability owing to aminoglycoside-induced membrane damage is thought to be one of the mechanisms by which aminoglycosides cooperate with β-lactams (see BOX 1 for more on drug synergy and antagonism).
Another consequence of mistranslated protein incorporation into the bacterial membrane is the activation of envelope (Cpx) and redox-responsive (Arc) two-component systems. These intracellular signal relay systems regulate the expression of genes that are important for the maintenance of membrane integrity and composition 111 , and membrane-coupled energy generation 112, 113 , respectively. Disruption of Cpx or Arc two-component system signalling (through a series of single-gene knockouts) has recently been shown to reduce the killing efficacy of aminoglycosides, a result associated with findings linking bactericidal antibiotic-induced cell death with drug stress-induced changes in metabolism. Interestingly, disruption of Cpx or Arc two-component system signalling was also shown to reduce the lethality of β-lactam and quinolone antibiotics 10 . Together, these findings point towards a broad role for the envelope stress-responsive and redox-responsive two-component systems in killing by bactericidal drugs (fIG. 2) .
Antibiotic network biology
As noted above, antibiotic-mediated cell death is a complex process that only begins with the drug-target interaction and the primary effects of these respective interactions. The development of new antibiotics and the improvement of current antibacterial drug therapies would benefit from a better understanding of the specific sequences of events beginning with the binding of a bactericidal drug to its target and ending in bacterial cell death.
Bioinformatics approaches that use high-throughput genetic screening or gene expression profiling have proven to be valuable tools to explore the response layers of bacteria to different antibiotic treatments 114 . For example, recent screens for antibiotic susceptibility in a singlegene deletion library of non-essential genes in E. coli 115 and a transposon mutagenesis library in P. aeruginosa 116 have provided important insights into the numbers and types of genes that affect treatment efficiency (bactericidal versus bacteriostatic effects), including those related to drug molecule efflux, uptake or degradation. In addition, monitoring global changes in gene expression patterns, or signatures, resulting from antibiotic treatment over a range of conditions, has advanced our understanding of the off-target effects elicited by primary drug-target interactions 114 .
Box 1 | Drug synergy
Combinatorial antibiotic treatments can have diverse effects on bacterial survival. Antibiotics can be more effective as a combination treatment displaying either an additive effect (an effect equal to the sum of the treatments) or a synergistic effect (an effect greater than the sum of the treatments). The combination can also be antagonistic -that is, the effect of the combination treatment is less than the effect of the respective single-drug treatments 136 . Technological advances have allowed high-throughput quantification of drug-drug interactions at the level of cell survival and target binding, thereby opening the door for the systematic study of synergistic and antagonistic drug combinations 137 . The exploration of the survival fitness landscape between drug combinations has allowed the study of the mechanisms by which antibiotics work against bacteria 138 and has also allowed a study of the evolution of drug resistance 137 . Further study of the synergy or antagonism between antibiotics will provide additional insight into the underlying cell death mechanisms for the individual classes of antibiotics. For example, the suppressive interaction between protein synthesis inhibitors and DNA synthesis inhibitors has been shown to be due to non-optimal ribosomal RNA regulation by DNA-inhibiting drugs 139 . The synergy between aminoglycosides and β-lactams has been attributed to β-lactam-mediated membrane damage leading to increased uptake of aminoglycosides 140 . It will be interesting to see whether the synergy between these two drugs is also related to the induction of the envelope stress response that has been observed following treatment with aminoglycosides 
Uq
A need also exists for the application of network biology methods to discern and resolve the potential interplay between genes and proteins coordinating bacterial stress response pathways. Typically, such methods incorporate gene expression profiling data and the results of highthroughput genetic screens, along with the contents of databases detailing experimentally identified regulatory connections and biochemical pathway classifications, to functionally enrich datasets and predict relationships that exist among genes under tested conditions. As such, biological network studies of drug-treated bacteria can be used to advance our understanding of how groups of genes interact functionally, rather than in isolation, when cells react to antibiotic stress 117 . Quinolones, β-lactams and aminoglycosides also trigger hydroxyl radical formation and cell death through the envelope (Cpx) and redox-responsive (Arc) two-component systems. It is also possible that redox-sensitive proteins, such as those containing disulphides, contribute in undetermined way to the common mechanism (dashed lines). To help address this problem, researchers have developed methods to construct quantitative models of regulatory networks [118] [119] [120] [121] [122] and have recently used these reconstructed network models to identify the sets of genes, associated functional groups and biochemical pathways that act in concert to mediate bacterial responses to antibiotics [8] [9] [10] 119 . Below we highlight some mechanistic insights that have been obtained from antibiotic network biology, and discuss some opportunities and challenges for this emerging area of research.
A common mechanism for antibiotic-mediated cell death. As an example of the utility of studying bacterial stress responses at the systems level, biological network analysis methods were recently employed to identify new mechanisms that contribute to bacterial cell death following topoisomerase II inhibition by the fluoroquinolone antibiotic norfloxacin 9 . As noted above, quinolones are known to induce cell death through the introduction of double-stranded DNA breaks following arrest of topoisomerase function 4 . To identify additional contributions to cell death resulting from topoisomerase II poisoning, reconstruction of stress response networks was carried out following treatment of E. coli with lethal concentrations of norfloxacin. This work identified an oxidative damage-mediated cell death pathway, which involves ROS generation and a breakdown in iron regulatory dynamics following norfloxacin-induced DNA damage. More specifically, norfloxacin treatment was found to promote superoxide generation soon after topoisomerase II poisoning and to ultimately result in the generation of highly destructive hydroxyl radicals through the fenton reaction 123 . under these conditions, the Fenton reaction was found to be fuelled by superoxide-mediated destabilization of Fe-S cluster catalytic sites, repair of these damaged Fe-S clusters and related changes in iron-related gene expression 9 . Building on this work, it was later shown that all major classes of bactericidal antibiotics (including β-lactams, aminoglycosides and quinolones) promote the generation of lethal hydroxyl radicals in both Gram-negative and Gram-positive bacteria, despite the stark differences in their primary drugtarget interactions 8 . Stress response network analysis methods used in this study suggested that antibioticinduced hydroxyl radical formation is the end product of a common mechanism, in which alterations in central metabolism related to NADH consumption (increased TCA cycle and respiratory activity) are crucial to superoxide-mediated iron-sulphur cluster destabilization and stimulation of the Fenton reaction. These predictions were validated by the results of additional phenotypic experiments, biochemical assays and gene expression measurements, confirming that lethal levels of bactericidal antibacterials trigger a common oxidative damage cellular death pathway, which contributes to killing by these drugs (fIG. 2) .
Most recently, the study of antibiotic-induced stress response networks has been aimed at determining exactly how the primary effect of a given bactericidal triggers aspects of cell death that are common to all bactericidal drugs. For example, a comparative analysis of stress response networks, reconstructed using gene expression data from E. coli treated with aminocyclitols (spectinomycin, gentamicin and kanamycin), 
Fenton reaction
Reaction of ferrous iron (fe 2+ ) with hydrogen peroxide to produce ferric iron (fe 3+ ) and a hydroxyl radical. Interestingly, mistranslated membrane proteins were shown to stimulate radical formation by activating the Cpx and Arc two-component systems, ultimately altering TCA cycle metabolism; the TCA cycle had previously been implicated in bacterial susceptibility to aminoglycosides 8, 124 . The discovery of the common oxidative damage cellular death pathway has important implications for the development of more effective antibacterial therapies. Specifically, it indicates that all major classes of bactericidal drugs can be potentiated by inhibition of the DNA stress response network (that is, the SOS response), which plays a key part in the repair of hydroxyl radical-induced DNA damage. This may be accomplished through the development of small molecules (for example, RecA inhibitors 125 ) or synthetic biology approaches
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ROS, such as superoxide and hydroxyl radicals, are highly toxic and have deleterious effects on bacterial physiology 123, 126, 127 , even under steady-state conditions. There is still much to be learned about how oxidative stress-related changes in bacterial physiology affect antibiotic-mediated cell death and the emergence of resistance 128, 129 . For example, it was recently discovered that endogenous nitric oxide produced by bacteria with nitric oxide synthases can protect against ROS-mediated cell death 130 . In addition, considering bacteria have developed mechanisms to avoid ROS produced by phagocytes of the immune system 131 , it will be interesting to explore, from a systems-level perspective, the relationship between immune-mediated and drug-mediated cell death.
Opportunities and challenges for antibiotic network biology. One of the more intriguing aspects of antibacterial therapies is that not all bacterial species respond in the same way to antibiotic treatment. Network biology approaches, which provide the field of antibiotic research with an opportunity to view response mechanisms of different bacterial species to various classes of antibiotics, could be extended to the context of particular infectious species, persistent infections or disease settings. As an example, it is generally accepted that Gram-negative bacteria are not susceptible to the glycopeptide vancomycin or the depolarizing lipopeptide daptomycin; however, a single gene, yfgL, was recently found that can make E. coli susceptible to glycolipid derivatives of vancomycin 132 . Gene expression profiling of daptomycin-treated S. aureus has revealed that daptomycin perturbs peptidoglycan synthesis through a mechanism involving the activation of cell wall stress systems and membrane depolarization 133 . Given these findings, we might be able to combine our knowledge of β-lactam-and aminoglycoside-induced gene signatures with the results of high-throughput screens at various drug doses to reconstruct drug-specific cell death networks that use Ygfl as a network anchor. Predicted functional and regulatory relationships between enriched genes could then be used to determine the secondary effects of lipopeptide antibiotics and gain insight into the different properties of this drug in Gram-negative and Gram-positive bacteria.
Moreover, the development of comparative network biology techniques will be essential to further our understanding of how species-specific differences manifest themselves in divergent drug-specific cell death networks and variations in physiological responses. These methods could be particularly useful when examining pathogenic bacteria with sparse systems-level data (such as Shigella or Salmonella spp.) that are closely related to well-studied bacteria (such as E. coli). Through a greater understanding of the biological networks that are related to an individual drug target, we eventually might be able to search for meaningful network homologues among species in Box 2 | Synthetic biology for antibacterial applications
The study of complex antibiotic-related cell death systems can be aided by synthetic biology. Delivery of engineered gene circuits that alter response network behaviour can serve as a tool to experimentally examine antibiotic-mediated cell death pathways, as well as a means to enhance killing by an antibiotic (see the figure) .
Bacteriophages, which are bacterium-specific viruses, show promise as an effective means to deliver network perturbations to bacteria to improve antibiotic lethality 141, 142 . Bacteriophages have been used to enhance killing of Escherichia coli by bactericidal antibiotics through the delivery of proteins that modify the oxidative stress response or inhibit DNA damage repair systems 142 . Bacteriophages are species specific, so it may be possible to use engineered bacteriophages to deliver antibioticenhancing synthetic gene networks, therapeutic proteins or antimicrobial peptides that are highly specific for an infecting organism. This would allow efficient treatment of a bacterial infection, while sparing the typical commensal body flora (see the figure) .
the same spirit as we currently search for gene homologues. Network-based efforts could also lead to the development of species-specific treatments, including synthetic biology-derived therapies (BOX 2), which could be useful in killing off harmful, invasive bacteria, while leaving our normal bacterial flora intact.
Finally, bacterial network analyses will also be useful in the study of non-classical antibacterial agents that induce cell death. Antimicrobial peptides are short cationic peptides that are thought to kill through interactions with the membrane that result in pore formation 134, 135 . However, the mode of action of many antimicrobial peptides could, in fact, be more complex, and cell death networks uncovered for existing antibiotics could be used as mechanistic templates to study cellular responses induced by antimicrobial peptides.
Concluding remarks
Drug-resistant bacterial infections are becoming more prevalent and are a major health issue facing us today. This rise in resistance has limited our repertoire of effective antimicrobials, creating a problematic situation that has been exacerbated by the small number of new antibiotics introduced in recent years. The complex effects of bactericidal antibiotics discussed in this Review provide a large playing field for the development of new antibacterial compounds, as well as adjuvant molecules and synthetic biology constructs, that could enhance the potency of current antibiotics. It will be important to translate our growing understanding of antibiotic mechanisms into new clinical treatments and approaches so that we can effectively fight the growing threat from resistant pathogens.
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